Phenosense Entry HIV Drug Resistance Assay
Use
The Phenosense Entry HIV Drug Resistance Assay is useful for determining phenotypic susceptibility to enfuvirtide (Fuzeon). It aids in assessing the potential effectiveness of enfuvirtide before it is incorporated into a patient's regimen or when modifying an existing regimen that includes enfuvirtide. This test is particularly beneficial in managing HIV treatment strategies to optimize therapeutic outcomes.
Special Instructions
For optimal results, the patient's viral load should be confirmed within two weeks prior to submission for testing at Monogram. Patient samples submitted less than 30 days apart are considered duplicates and will be canceled. This test is intended for use only in patients with viral loads greater than or equal to 500 copies/mL.
Limitations
Samples with a viral load less than 500 copies/mL are not suitable for this test. Additionally, this assay requires specific specimen handling and processing; plasma must be separated and frozen immediately after collection. High-quality plasma specimens are essential for accurate results, and improper handling, such as failure to centrifuge or non-frozen specimens, can lead to test rejection.
New York Approved
Methodology
PCR-based
Biomarkers
LOINC Codes
- 45182-3
- 45182-3
Result Turnaround Time
18-30 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL
Minimum Volume
1.0 mL
Container
Lavender-top (EDTA) or plasma preparation tube (PPT)
Collection Instructions
Draw blood into two 5-mL PPT (pearl top) or EDTA (lavender top) tube. Centrifuge specimen within six hours of collection. Transfer plasma to one or more polypropylene screw-capped tube(s) and freeze. Freeze immediately. Send 3 mL plasma in a screw-cap vial frozen.
Causes for Rejection
PPT not centrifuged; insufficient volume; heparinized plasma; non frozen specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |